![Lindsey Rolfe](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lindsey Rolfe
Chief Tech/Sci/R&D Officer at
3B Pharmaceuticals GmbH
Net worth: - $ as of 30/08/2026
Profile
Lindsey Rolfe is currently an Independent Director at CERo Therapeutics Holdings, Inc. since 2024 and Chief Medical Officer at 3B Pharmaceuticals GmbH since 2023.
Former roles include Independent Director at Atreca, Inc. from 2019 to 2024, Member of The Royal College of Physicians, and Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc. from 2015 to 2023.
Education includes a doctorate from The University of Edinburgh.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
-.--% | 27/04/2026 | 0 ( -.--% ) | - $ | 30/08/2026 |
Lindsey Rolfe active positions
| Companies | Position | Start |
|---|---|---|
3B Pharmaceuticals GmbH
 3B Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Researches and develops radiopharmaceutical drugs and diagnostics for oncology indications | Chief Tech/Sci/R&D Officer | 31/07/2023 |
Former positions of Lindsey Rolfe
| Companies | Position | End |
|---|---|---|
| ATRECA, INC. | Director/Board Member | 30/04/2024 |
| CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 31/05/2023 |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Training of Lindsey Rolfe
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
46
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Atreca, Inc.
 Atreca, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel antibody-based immune therapeutics to treat a range of solid tumor cancers | Health Technology |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Researches and develops radiopharmaceutical drugs and diagnostics for oncology indications | Commercial Services |
- Stock Market
- Insiders
- Lindsey Rolfe
